Keyword: Moderna Therapeutics
Sun brings experience from the FDA, CDC and Walter Reed Army Institute of Research to his role at the biotech unicorn.
Moderna, which is pushing a pipeline of mRNA candidates into phase 2 trials, now has a manufacturing plant ready to advance its program.
The deal includes a $45 million upfront payment and R&D work in up to five undisclosed infectious disease targets.
VBI-1501 showed neutralizing antibody activities against both fibroblast and epithelial cell infections.
PaxVax picked up the FDA's fast track tag for its chikungunya vaccine.
Moderna has several vaccines in phase 1 development, including against CMV, HMPV/PIV3, influenza, Zika and chikungunya.
Here is some other vaccine news of note for the week.
After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.
Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.